AI Article Synopsis
- Androgen deprivation therapy is a vital treatment for advanced prostate cancer, but men experience complex symptoms that significantly affect their quality of life.
- A qualitative synthesis of literature from 2001 to 2023 identified 24 studies and categorized men's symptom experiences into four key findings: symptoms are often underestimated, perceptions are complicated, meanings of symptoms can be threatening, and responses to symptoms vary widely.
- Understanding these experiences is crucial for healthcare providers to enhance shared decision-making and support, highlighting the need for future research on personalized care approaches.
Article Abstract
Background: Androgen deprivation therapy is a common treatment for men with advanced prostate cancer. They have experienced many complex symptoms that affect their quality of life. However, qualitative reviews that synthesize the symptom experience for men with prostate cancer are lacking.
Objective: To explore the men's symptom experience throughout androgen deprivation therapy for prostate cancer.
Design: A qualitative evidence synthesis using meta-aggregation.
Data Resources: Published and unpublished literature between January 2001 and August 2023 were identified from PubMed, Embase (Ovid), Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), The Cochrane Library, ProQuest, Google Scholar, China National Knowledge Infrastructure (CNKI), Wang Fang, and VIP.
Review Methods: Two reviewers independently conducted screening, study selection and data extraction, and quality appraisal was performed using the Joanna Briggs Institutes Critical Appraisal Checklist for Qualitative Research. Data synthesis was conducted using meta-aggregative approach.
Results: 24 articles of moderate to high methodological quality were included. A total of 98 findings were extracted with 59 unequivocal or equivocal findings eligible for meta-aggregation, aggregated into nine categories, and developed four synthesized findings: (1) production of symptoms: unrecognized and underestimated, (2) perception of symptoms: varied and complicated, (3) meaning of symptoms: threatened and affected, and (4) response to symptoms: push and pull.
Conclusions: Men throughout androgen deprivation for prostate cancer experience the four crisis-packed stages in their symptomatic journey. Health care provider need to understand the men's thoughts whether in the process of shared decision-making or in the course of the chosen therapy. Future research should develop individual suitable interventions and offer practical strategies for managing symptom. PROSPERO registration: CRD42023449129.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijnurstu.2024.104796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
BMC Cancer
January 2025
Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
Background: This paper describes the rationale and design of the RECOVER study. Currently, there is no consensus regarding the optimal treatment for high-risk, non-metastatic prostate cancer (PCa). The study primarily aims to evaluate and compare the impact of treatment with robot-assisted radical prostatectomy (RP) versus external beam radiation therapy (EBRT) with androgen deprivation therapy (ADT) for men with high-risk, non-metastatic PCa regarding health-related quality of life (HRQoL) and functional outcomes.
View Article and Find Full Text PDFCase report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level.
Front Oncol
January 2025
Department of Urology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Penile metastasis originating from prostate cancer is an extremely rare condition, typically associated with a poor prognosis. Therapeutic approaches are not well established and may require individualized adaptation based on clinical assessment. Radiotherapy is commonly utilized to alleviate symptoms.
View Article and Find Full Text PDFUnlabelled: Biomolecular condensates organize cellular environments and regulate key processes such as transcription. We previously showed that full-length androgen receptor (AR-FL), a major oncogenic driver in prostate cancer (PCa), forms nuclear condensates upon androgen stimulation in androgen-sensitive PCa cells. Disrupting these condensates impairs AR-FL transcriptional activity, highlighting their functional importance.
View Article and Find Full Text PDFIncidental discovery of gastrointestinal stromal tumor via PSMA-PET/CT imaging: Insights from a case report.
Urol Case Rep
January 2025
The Cancer Ecology Center, The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, 21287, USA.
PSMA-PET/CT has emerged as a superior diagnostic tool for prostate cancer, demonstrating enhanced accuracy over conventional imaging methods. Although sensitive for detecting local and metastatic prostate tumors, it can also identify other non-prostate PSMA positive lesions. Here, we report a rare case of a 67-year-old patient with metastatic prostate adenocarcinoma who was found to have an incidental Gastrointestinal Stromal Tumor (GIST), during restaging with 68Ga-PSMA-11 PET/CT.
View Article and Find Full Text PDFRelationship Between Pre- and Post-Orchidectomy Serum Dihydrotestosterone and Prostate Cancer Severity in a Cohort of Nigerian Patients.
West Afr J Med
September 2024
Urology Department, Dorset County Hospital, Dorchester, UK.
Introduction: Prostate cancer (PCa) is the commonest urologic cancer worldwide and the leading cause of male cancer deaths in Nigeria. In Nigeria, orchidectomy remains the primary androgen deprivation therapy. Dihydrotestosterone (DHT) is the active prostatic androgen, but its relationship with PCa severity has not been extensively studied in Africa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!